December 27, 2017 / 1:09 PM / in 10 months

BRIEF-Horizon Pharma Announces FDA Approval to Expand the Indication for Procysbi

Dec 27 (Reuters) - Horizon Pharma Plc:

* HORIZON PHARMA PLC ANNOUNCES FDA APPROVAL TO EXPAND THE INDICATION FOR PROCYSBI® (CYSTEAMINE BITARTRATE) DELAYED-RELEASE CAPSULES TO INCLUDE CHILDREN ONE YEAR OF AGE AND OLDER LIVING WITH NEPHROPATHIC CYSTINOSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below